Dinara Ryspayeva

Assistant Professor

Brown University

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dinara Ryspayeva is an Assistant Professor at Brown University in the United States. Her research focuses on cancer therapeutics, including the investigation of HER2-overexpressing cancer treatments, the role of PRMT5 in bladder urothelial carcinoma, and the effects of signaling pathway dysregulation in breast cancer. She has contributed significantly to studies on vaccine-based therapies and the efficacy of targeted molecular therapies in advanced cancer treatments.

Articles (15)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (1)

Attila A Seyhan

Associate Professor and Director of Translational Oncology Operations and Associate Professor (Research)

Brown University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Dinara Ryspayeva

Research Interests

Explore related searches

Contact this professor

About

Articles (15)

Abstract P1-07-15: Tumor size reduction and overall survival improvement in HER2-overexpressing cancer patients vaccinated with HER-Vaxx, a B-cell peptide-based vaccine, plus standard-of-care chemotherapy

Abstract 1692: PRMT5 inhibitor displays synergy with PARP inhibitor in bladder urothelial carcinoma models

Abstract 4239: Effect of MTAP expression on PRMT5 inhibitor sensitivity in bladder urothelial carcinoma models

Acquired resistance to molecularly targeted therapies for cancer

Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer

Signaling pathway dysregulation in breast cancer

Targeting apoptotic pathways for cancer therapy

Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)

Real-world Observational Multi-center Study: Retrospective Analysis of Diagnostic and Treatment Patterns for Stage III–IV Melanoma in Ukraine from 2018 to 2020

Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)

141P Molecular landscape of hereditary breast cancer in Ukrainian women

Оптимальна інтеграція інгібіторів CDK4/6 у лікування гормон-рецепторпозитивного метастатичного раку молочної залози

Abstract CT107: A PHASE 1B/2 OPEN-LABEL STUDY WITH RANDOMIZATION IN PHASE 2 OF IMU-131 HER2/NEU PEPTIDE VACCINE PLUS STANDARD OF CARE CHEMOTHERAPY IN PATIENTS WITH HER2/NEU OVEREXPRESSING METASTATIC OR ADVANCED ADENOCARCINOMA OF THE STOMACH OR GASTROESOP…

HERIZON: A phase 1B/2 open-label study of imu-131 HER2/neu peptide vaccine PLUS standard of care chemotherapy with randomization in phase 2 in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.

Rintodestrant (G1T48), an oral selective estrogen receptor degrader, in combination with palbociclib for ER+/HER2– advanced breast cancer: Phase 1 results.

Collaborators (1)

Attila A Seyhan

Make your next move.